HealthTree Logo
search more_vert
App Logo
close
person Sign In / Create Account
Clinical Trial: SubQ Daratumumab vs. Active Monitoring for High-Risk Smoldering Myeloma Patients
Posted: Oct 14, 2017
Clinical Trial: SubQ Daratumumab vs. Active Monitoring for High-Risk Smoldering Myeloma Patients image

A smoldering myeloma study is open to determine whether subcutaneous daratumumab prolongs progression free survival vs. active monitoring for high-risk smoldering myeloma patients. Most doctors take a "watch and wait" approach when it comes to treating smoldering myeloma patients because many of them will never progress to active myeloma. But some smoldering myeloma patients are considered high risk and are expected to progress within two year of diagnosis. For these patients, treatment is suggested under clinical trials.

There are 19 sites announced for this trial including facilities in California, Florida, Georgia, Louisiana, Massachusetts, Michigan, Minnesota, Missouri, Nebraska and North Carolina. Ohio, Oregon, Pennsylvania, Texas and Washington.

Learn more and connect with this trial directly here: 

SubQ High-Risk Smoldering Clinical Trial

Find eligible clinical trials for your smoldering myeloma here: 

Find Myeloma Clinical Trials

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Janssen Oncology
Amgen Oncology
Abbvie
Genentech
GSK
Bristol Myers Squibb

Follow Us

facebook instagram twitter youtube